Related Experiment Video

Updated: Jul 11, 2026

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Molecular biology. Cancer fighter's modus operandi revealed

J Marx

    Science (New York, N.Y.)
    |September 30, 2000
    PubMed

    Insights

    A new cancer drug, STI-571, functions like a smart bomb, targeting specific cancer cells. This breakthrough in understanding its mechanism could lead to improved cancer therapies.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Chronic myelogenous leukemia (CML) is a cancer with specific molecular drivers.
    • Targeted cancer therapies aim to inhibit key proteins involved in cancer progression.
    • STI-571 has demonstrated significant efficacy in early clinical trials for CML.

    Discussion:

    • The study elucidates the precise mechanism of action for the cancer drug STI-571.
    • Researchers reveal how STI-571 selectively targets a narrow range of cellular components.
    • Understanding this selectivity is crucial for optimizing drug efficacy and minimizing side effects.

    Key Insights:

    • STI-571 acts as a highly specific inhibitor, akin to a 'smart bomb'.
    • The drug's targeted action is key to its success in treating chronic myelogenous leukemia.
    • Deciphering the drug's mechanism provides a blueprint for future drug development.

    Outlook:

    • This research paves the way for designing novel, targeted cancer therapies.
    • Further studies may explore STI-571's potential in other cancer types.
    • The findings offer a foundation for developing next-generation kinase inhibitors.

    More Related Videos

    Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

    Comparative Lesions Analysis Through a Targeted Sequencing Approach

    Published on: November 5, 2019

    Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

    Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

    Published on: May 2, 2022

    Related Concept Videos

    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    Metastasis02:30

    Metastasis

    Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
    Epithelial-to-Mesenchymal Transition
    The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
    TGF - β Signaling Pathway01:16

    TGF - β Signaling Pathway

    The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
    IP3/DAG Signaling Pathway01:11

    IP3/DAG Signaling Pathway

    Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...